DCOY Decoy Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Decoy Therapeutics Inc reported revenue of $228K, net income of −$2.37M and diluted EPS of −$4.46; for the fiscal year ended December 2025 revenue was n/a.
DCOY annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$12.6M, net income $12.5M (margin n/a), EPS −$129.10
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$5.73M, net income $5.58M (margin n/a), EPS −$69.54
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$12.9M, net income $12.5M (margin n/a), EPS −$30.74
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$31.8M, net income −$31.6M (margin n/a), EPS −$14.88
- Fiscal year ended Dec 2021: revenue $1.84M, gross profit n/a, operating income −$12.8M, net income −$12.8M (margin -693.8%), EPS −$7.72
DCOY quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $228K, net income −$2.37M, EPS −$4.46
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.22M, EPS −$4.18
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $16.1M, EPS $193.99
- Quarter ended Sep 30, 2025: revenue n/a, net income −$873K, EPS −$1.81
- Quarter ended Jun 30, 2025: revenue $0, net income −$958K, EPS −$81.21
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.71M, EPS −$240.07
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $9.69M, EPS −$52.52
- Quarter ended Sep 30, 2024: revenue n/a, net income −$972K, EPS −$11.38
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.42M, EPS −$2.37
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.72M, EPS −$3.27
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $24.2M, EPS −$11.85
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.44M, EPS −$5.21
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.88M, EPS −$11.45
- Quarter ended Mar 31, 2023: revenue $0, net income −$5.34M, EPS −$2.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$6.37M, EPS −$2.97
- Quarter ended Sep 30, 2022: revenue $0, net income −$14.4M, EPS −$6.41
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$4.72M, EPS −$2.20
- Quarter ended Mar 31, 2022: revenue $0 (down 100.0% year over year), net income −$6.11M, EPS −$3.30
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$4.10M, EPS −$5.50
- Quarter ended Sep 30, 2021: revenue $0, net income −$3.74M, EPS −$2.09
DCOY cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$4.83M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.53M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$12.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$17.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$10.2M, share buybacks n/a
DCOY balance sheet
- Jun 30, 2026: cash $8.29M, total assets $9.00M, total liabilities $4.68M, shareholders' equity $4.32M
- Mar 31, 2026: cash $7.82M, total assets $8.42M, total liabilities $4.55M, shareholders' equity $3.88M
- Dec 31, 2025: cash $10.7M, total assets $11.1M, total liabilities $5.17M, shareholders' equity $5.89M
- Sep 30, 2025: cash $4.81M, total assets $6.10M, total liabilities $1.85M, shareholders' equity $4.25M
- Jun 30, 2025: cash $795K, total assets $1.39M, total liabilities $2.22M, shareholders' equity −$830K
- Mar 31, 2025: cash $1.80M, total assets $2.34M, total liabilities $2.28M, shareholders' equity $61.9K
- Dec 31, 2024: cash $2.43M, total assets $3.02M, total liabilities $1.51M, shareholders' equity $1.51M
- Sep 30, 2024: cash $3.28M, total assets $3.86M, total liabilities $935K, shareholders' equity $2.92M
Is DCOY profitable?
Yes. Decoy Therapeutics Inc earned $10.6M over the last four quarters.
What is DCOY's EPS?
Diluted earnings per share over the last four quarters were $183.54; −$4.46 in the latest quarter.